BioXcel’s BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2) Sep 13, 2016
BioXcel Begins Strategic Collaboration with Alnylam to Discover Novel RNAi Therapeutic Products May 24, 2016
BioXcel to Present at the 3rd International Conference on the Progress of Regenerative Medicine and its Cultural Impact at the Vatican Apr 27, 2016
BioXcel Strengthens Position in Immuno-Oncology With Dedicated Big Data Analytics Platform Jan 21, 2016
